Scilex (SCLX) Total Assets (2020 - 2026)
Scilex (SCLX) total assets from Mar 31, 2020 to Mar 31, 2026. The current Scilex (SCLX) total assets is $294M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Total Assets
Total Assets
Scilex (SCLX) Total Assets CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +170.17% |
| 3 Years TTM | +34.73% |
| 5 Years TTM | +451.27% |
| All Time TTM | +451.40% |
Annual Total Assets change of Scilex (SCLX)
| Year | Total Assets | Change |
|---|---|---|
| 2025 | $365M | +292.66% |
| 2024 | $93M | -8.25% |
| 2023 | $101M | +17.08% |
| 2022 | $87M | +43165.00% |
| 2020 | $200K | N/A |
Comparison Scilex (SCLX) total assets with competitors
Scilex (SCLX) total assets is $293.64M.
| Ticker | Name | Total Assets | Upside |
|---|---|---|---|
| NVO | Novo Nordisk | $559.22B | +190344.42% |
| PFE | Pfizer Inc | $207.62B | +70604.94% |
| JNJ | Johnson & Johnson | $200.89B | +68315.07% |
| ABBV | Abbvie Inc | $136.46B | +46372.89% |
| MRK | Merck & Co Inc | $128.69B | +43724.07% |
| SNY | Sanofi | $128.02B | +43498.96% |
| NVS | Novartis AG | $118.53B | +40266.44% |
| LLY | Lilly(Eli) & Company | $116.58B | +39600.31% |
| AZN | Astrazeneca plc | $114.02B | +38728.16% |
| AMGN | AMGEN Inc | $92.50B | +31402.52% |
| BMY | Bristol-Myers Squibb Company | $86.48B | +29349.67% |
| GSK | GSK Plc | $82.91B | +28133.67% |
| GILD | Gilead Sciences Inc | $56.28B | +19065.65% |
| BIIB | Biogen Inc | $29.48B | +9940.56% |
| GRFS | Grifols SA | $20.10B | +6744.76% |
| OGN | Organon & Company | $13.00B | +4325.83% |
| AMRN | Amarin Corp | $645.76M | +119.92% |
| MIRA | Mira Pharmaceuticals Inc | $9.46M | -96.78% |
| MDCX | MDCorp | $7.43M | -97.47% |
| MDCXW | Medicus Pharma Ltd warrant | $7.43M | -97.47% |
| NSRX | Nasus Pharma Ltd | $5.00M | -98.30% |